<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Is There Still Room for Growth in West Pharma After Recent Regulatory Approval? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Is There Still Room for Growth in West Pharma After Recent Regulatory Approval?</h2>
    <div class="badge">2025-09-20T11:51:26+00:00</div>
    <ul>
      <li>Analyst estimates suggest this figure could grow to $542 Million by 2028.</li>
<li>Story Continues WST Discounted Cash Flow as at Sep 2025 Our Discounted Cash Flow (DCF) analysis suggests West Pharmaceutical Services may be overvalued by 35.7%.</li>
<li>For example, community Narratives for West Pharmaceutical Services range from bullish forecasts, expecting revenue to grow 6.5% a year, margins to improve, and a fair value of $350, to more cautious views with lower price targets as low as $260, reflecting different beliefs about the company’s risks and opportunities.</li>
<li>West Pharmaceutical Services eked out a 0.5% gain over the past week, and the last 30 days saw the stock climb 3.4%.</li>
<li>After facing a shaky start this year, with the stock down 22.4% year-to-date and 17.0% in the last 12 months, investors are rightfully questioning what comes next.</li>
<li>For West Pharmaceutical Services, the latest reported Free Cash Flow (FCF) stands at $323.6 Million.</li>
<li>NYSE:WST Community Fair Values as at Sep 2025 This article by Simply Wall St is general in nature.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Is%20There%20Still%20Room%20for%20Growth%20in%20West%20Pharma%20After%20Recent%20Regulatory%20Approval%3F%0A%E2%80%A2%20Analyst%20estimates%20suggest%20this%20figure%20could%20grow%20to%20%24542%20Million%20by%202028.%0A%E2%80%A2%20Story%20Continues%20WST%20Discounted%20Cash%20Flow%20as%20at%20Sep%202025%20Our%20Discounted%20Cash%20Flow%20%28DCF%29%20analysis%20suggests%20West%20Pharmaceutical%20Services%20may%20be%20overvalued%20by%2035.7%25.%0A%E2%80%A2%20For%20example%2C%20community%20Narratives%20for%20West%20Pharmaceutical%20Services%20range%20from%20bullish%20forecasts%2C%20expecting%20revenue%20to%20grow%206.5%25%20a%20year%2C%20margins%20to%20improve%2C%20and%20a%20fair%20value%20of%20%24350%2C%20to%20more%20cautious%20views%20with%20lower%20price%20targets%20as%20low%20as%20%24260%2C%20reflecting%20different%20beliefs%20about%20the%20company%E2%80%99s%20risks%20and%20opportunities.%0A%E2%80%A2%20West%20Pharmaceutical%20Services%20eked%20out%20a%200.5%25%20gain%20over%20the%20past%20week%2C%20and%20the%20last%2030%20days%20saw%20the%20stock%20climb%203.4%25.%0A%E2%80%A2%20After%20facing%20a%20shaky%20start%20this%20year%2C%20with%20the%20stock%20down%2022.4%25%20year-to-date%20and%2017.0%25%20in%20the%20last%2012%20months%2C%20investors%20are%20rightfully%20questioning%20what%20comes%20next.%0A%E2%80%A2%20For%20West%20Pharmaceutical%20Services%2C%20the%20latest%20reported%20Free%20Cash%20Flow%20%28FCF%29%20stands%20at%20%24323.6%20Million.%0A%E2%80%A2%20NYSE%3AWST%20Community%20Fair%20Values%20as%20at%20Sep%202025%20This%20article%20by%20Simply%20Wall%20St%20is%20general%20in%20nature.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fis-there-still-room-for-growth-in-west-pharma-after-recent-regulatory-approval%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/still-room-growth-west-pharma-115126362.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>